Overview
Yue Fei practices practicing medicine in Tianjin, China.
Fei is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).
They are actively involved in clinical research, co-authoring 15 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Yue Fei
Is Yue Fei a top-rated expert for Mantle Cell Lymphoma (MCL)?
MediFind is an objective health platform that identifies experts based on real-world data. Yue Fei is classified as an Advanced expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Yue Fei participate in research or clinical trials?
Yes. Yue Fei has published 15 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Yue Fei's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Mantle Cell Lymphoma (MCL)
- Experienced
- B-Cell LymphomaFei isExperienced. Learn about B-Cell Lymphoma.
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Non-Hodgkin LymphomaFei isExperienced. Learn about Non-Hodgkin Lymphoma.